(Alliance News) - Renalytix PLC on Friday said that the US Patent Office allowed its patent clams for intellectual property exclusively licensed to the company.
The London-based kidney health-focused diagnostics company said the US Patent Office issued a new notice of allowance of claims surrounding the biomarkers sTNFR1 and sTNFR2 used in the kidneyintelX.dkd test.
"The newly allowed claims further strengthen the core intellectual property underpinning the KidneyIntelX technology by directly incorporating sTNFR1 and sTNFR2 into a set of consolidated claims directed towards identifying risk of early kidney function decline, thereby enabling therapeutic strategies for those at increased risk of progressive decline," Renalytix said.
Renalytix shares fell 8.6% to 48.00 pence each on Friday morning in London.
By Tom Budszus, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Renalytix Plc (RENX)